Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (6)

2019

  1. Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

    European Journal of Cancer, Vol. 107, pp. 186-195

2013

  1. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck

    European Journal of Cancer, Vol. 49, Núm. 13, pp. 2877-2883

2006

  1. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer

    International Journal of Gynecological Cancer, Vol. 16, Núm. 1, pp. 71-76

2005

  1. Assessment of the value of confirming responses in clinical trials in oncology

    European Journal of Cancer, Vol. 41, Núm. 11, pp. 1528-1532

2002

  1. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: Systematic review of the literature and implications for future research

    Gynecologic Oncology, Vol. 84, Núm. 2, pp. 201-209

  2. The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research

    Cancer, Vol. 95, Núm. 7, pp. 1605-1610